LP-168

DRUG2 trials

Conditions

CLL/SLLChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaHairy Cell LeukemiaMantle Cell LymphomaMarginal Zone Lymphoma

Phase 1

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

RecruitingNCT04775745

Newave Pharmaceutical IncCLL/SLL, Diffuse Large B Cell Lymphoma, Follicular Lymphoma +4

Start: 2021-07-19End: 2027-12-31Target: 60Updated: 2026-02-13

Phase 2

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

RecruitingNCT06978088

Zulfa OmerChronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, CLL/SLL +1

Start: 2025-06-01End: 2034-06-01Target: 34Updated: 2025-08-14

Journal of Clinical Oncology2026-05-28

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Blood2025-11-03

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood2025-11-03

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Blood2024-11-056 citations

Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase

Blood2023-11-0210 citations

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Blood2023-11-024 citations

LP-168

Sponsors

Conditions

Phase 1

Phase 2

Related Papers